headquarters cambridge massachusetts website http www.tolerx.com tolerx inc. was a biopharmaceutical company headquartered in cambridge massachusetts . the company was focused on discovering and developing new therapies designed to treat patients by reprogramming the immune system allowing for long term remission of immune related diseases after a short course of therapy . targeted diseases include type 1 diabetes rheumatoid arthritis inflammatory bowel disease ibd cancer chronic and viral diseases . in 2008 tolerx was named one of fierce biotech s fierce 15 . 1 in october 2011 tolerx was shut down due to an unsuccessful phase iii trial in patients recently diagnosed with type 1 diabetes . 2 development programs edit tolerx s lead product candidate otelixizumab also known as trx4 is a novel monoclonal antibody being developed for the treatment of autoimmune type 1 diabetes and other autoimmune diseases . the efficacy and safety of otelixizumab in the treatment of type 1 diabetes is currently being studied in a pivotal phase 3 study called defend durable response therapy evaluation for early or new onset type 1 diabetes . 3 4 tolerx entered into a collaboration with glaxo smithkline in october 2007 relating to the development and commercialization of otelixizumab . 5 otelixizumab has been granted orphan drug status by the u.s. food and drug administration . 6 additionally in collaboration with genentech tolerx is developing a modified version of trx1 a humanized monoclonal antibody that binds to the cd4 receptor found on both t effector and t regulatory cells . the safety and activity of trx1 was evaluated by tolerx in a single dose placebo controlled double blind phase 1 clinical trial . the data from the phase 1 clinical trial showed trx1 was well tolerated did not deplete t cells and had no observed first dose side effect . 7 the modified version of trx1 designated mtrx1011a is being developed for the treatment of autoimmune diseases which may include rheumatoid arthritis cutaneous lupus erythematosus cle multiple sclerosis ms and systemic lupus erythematosus sle . 8 the tolerx pipeline also includes two pre clinical candidates trx518 an antibody directed to gitr glucocorticoid induced tumor necrosis factor receptor a surface receptor molecule that has been shown to be involved in inhibiting the suppressive activity of t regulatory cells and extending the survival of t effector cells 9 and trx385 a monoclonal antibody that recognizes ilt3 an inhibitory receptor expressed by dendritic cells and monocytes . these pre clinical candidates may be developed for the treatment of cancer and viral diseases . leadership edit herman waldmann phd frcpath mrcp frs fmedsci 10 co founder chairman scientific advisory board professor of pathology head of the sir william dunn school of pathology and clinical director of the therapeutic antibody centre tac university of oxford a pioneer in the field of monoclonal antibody production 11 douglas j. ringler vmd 12 13 co founder president & ceo louis vaickus md 12 14 chief medical officer thomas a. shea mba 15 chief financial officer references edit fierce biotech s 2008 fierce 15 1 from clinicaltrials.gov a service from the u.s. national institutes of health www.defendagainstdiabetes.com windhover information gsk buys rights to tolerx s diabetes antibody otelixizumab mass high tech may 16 2008 n.e. drug makers find individual paths into growing diabetes arena vaickus l. ; stefanich e ; anand bs ; fielder pj ; vaickus l jan 2006 . pharmacokinetics pharmacodynamics of nondepleting anti cd4 monoclonal antibody trx1 in healthy human volunteers . pharm res . 23 1 95 103 . doi 10.1007 s11095 005 8814 3 . pmid 16308668 . windhover information genentech licenses tolerx s trx1 for autoimmune disease jun shimizu ph.d 2002 . stimulation of cd25 cd4 regulatory t cells through gitr breaks immunological self tolerance web . tokyo metropolitan institute of gerontology . retrieved 2009 04 15 . business week personal profile university of cambridge success stories a b onemedplace profile business week personal profile business week personal profile business week personal profile retrieved from https en.wikipedia.org w index.php title tolerx & oldid 588606135 categories biotechnology companies of the united statesdefunct companies based in massachusettscompanies based in cambridge massachusettscompanies established in 2000companies disestablished in 2011privately held companies based in massachusetts navigation menu personal tools not logged intalkcontributionscreate accountlog in namespaces article talk variants views read edit view history more search navigation main pagecontentsfeatured contentcurrent eventsrandom articledonate to wikipediawikipedia store interaction helpabout wikipediacommunity portalrecent changescontact page tools what links hererelated changesupload filespecial pagespermanent linkpage informationwikidata itemcite this page print export create a bookdownload as pdfprintable version languages add links this page was last modified on 1 january 2014 at 02 08 . text is available under the creative commons attribution sharealike license ; additional terms may apply . by using this site you agree to the terms of use and privacy policy . wikipedia is a registered trademark of the wikimedia foundation inc. a non profit organization . privacy policy about wikipedia disclaimers contact wikipedia developers cookie statement mobile view